Expertise in
26
conditions

Dr. Thomas Galloway

Radiation Oncology
Fox Chase Cancer Center
333 Cottman Ave, 
Philadelphia, PA 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
26
conditions
Fox Chase Cancer Center
333 Cottman Ave, 
Philadelphia, PA 

Overview

Thomas Galloway is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania.

Dr. Galloway is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Laryngeal Cancer, Throat Cancer, Adenoid Cystic Carcinoma, Tongue Cancer, and Glossectomy.

He is actively involved in clinical research, co-authoring 93 peer reviewed articles and participating in 8 clinical trials.

Graduate Institution

University Of Florida College Of Medicine

Specialties

Radiation Oncology

Licenses

Radiology in FL

Hospital Affiliations

Hospital Of Univ Of Pennsylvania
Temple University Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Cigna
  • EPO
  • HMO
  • PPO
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Fox Chase Cancer Center
333 Cottman Ave, Philadelphia, PA 19111
Other Locations
Office
Avenue Fox Chase Can Ctr, Philadelphia, PA 19111

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: March 23, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Other, Procedure, Drug, Biological, Radiation
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 2/Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2026
Intervention Type: Biological, Radiation
Study Drug: Cetuximab
Study Phase: Phase 3
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Enrollment Status: Completed
Publish Date: March 06, 2025
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
ROMAN: Reduction in Oral Mucositis With Avasopasem Manganese (GC4419) - Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced, Non-Metastatic Head and Neck Cancer
Enrollment Status: Completed
Publish Date: October 24, 2023
Intervention Type: Drug
Study Drug: GC4419
Study Phase: Phase 3
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation
Enrollment Status: Completed
Publish Date: October 17, 2023
Intervention Type: Drug, Radiation
Study Drugs: Cisplatin, Lapatinib
Study Phase: Phase 2
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Completed
Publish Date: June 10, 2022
Intervention Type: Drug, Other, Radiation, Biological
Study Drugs: Cisplatin, Pembrolizumab
Study Phase: Phase 1
View 7 Less Clinical Trials

93 Total Publications

Systemic Treatment of Thyroid Cancer: ASCO Guideline.
Systemic Treatment of Thyroid Cancer: ASCO Guideline.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 01, 2026
Similar Doctors
Expertise in
38
conditions
Dr. Keith Cengel
Radiation Oncology
Expertise in
38
conditions
Dr. Keith Cengel
Radiation Oncology

Abramson Cancer Center Penn Presbyterian

51 N. 39th Street, Pavilion For Advanced Care, First Floor, 
Philadelphia, PA 
 (4.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Keith Cengel is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Cengel is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Mesothelioma, Lung Cancer, Metastatic Pleural Tumor, Small Cell Lung Cancer (SCLC), and Liver Embolization. Dr. Cengel is board certified in Radiation Oncology, 2008. Dr. Cengel is currently accepting new patients.

Expertise in
21
conditions
Dr. Abigail Berman
Radiation Oncology
Expertise in
21
conditions
Dr. Abigail Berman
Radiation Oncology

Fox Chase Cancer Center

333 Cottman Ave, 
Philadelphia, PA 
 (5.5 miles away)
215-728-3544
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Abigail Berman is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. She has been practicing medicine for over 17 years. Dr. Berman is highly rated in 21 conditions, according to our data. Her clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Thymic Epithelial Tumor, and Small Cell Lung Cancer (SCLC).

Expertise in
33
conditions
Dr. Wenyin Shi
Radiation Oncology
Expertise in
33
conditions
Dr. Wenyin Shi
Radiation Oncology

Radiation Oncology At Thomas Jefferson University Hospital

111 South 11th Street, Suite G-301, 
Philadelphia, PA 
 (3.9 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Wenyin Shi is a Radiation Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Shi is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Astrocytoma, Mycosis Fungoides, Glioblastoma, Brain Tumor, and Gamma Knife Radiosurgery. Dr. Shi is board certified in Radiology and Radiation Oncology. Dr. Shi is currently accepting new patients.

Frequently Asked Questions about Dr. Thomas Galloway

How do I make an appointment with Dr. Thomas Galloway?

You can book an appointment with Dr. Thomas Galloway by calling their office at 215-728-5536. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Thomas Galloway a top-rated expert for Laryngeal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Thomas Galloway is classified as an Distinguished expert for Laryngeal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Thomas Galloway specialize in?

While Dr. Thomas Galloway is a Radiation Oncology, they have specific expertise in Laryngeal Cancer, Throat Cancer, and Adenoid Cystic Carcinoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Thomas Galloway participate in research or clinical trials?

Yes. Dr. Thomas Galloway has published 93 articles and abstracts on conditions like Laryngeal Cancer. You can view a list of Dr. Thomas Galloway's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Thomas Galloway accept my insurance?

Dr. Thomas Galloway accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 215-728-5536 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Galloway's expertise for a condition
ConditionClose
    View All 13 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 44 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile